PP
CRMD icon

Paloma Partners’s CorMedix CRMD Stock Holding History

Paloma Partners’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-26,573
Closed -$264K – 1883
2016
Q2 		$264K Buy
26,573
+23,432
+746% +$357K ﹤0.01% 1830
2016
Q1 		$42K Buy
+3,141
New +$30.5K ﹤0.01% 1801

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GLRA
Gerald L. Ray & Associates Dallas, Texas $802M AUM 21.01% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Paloma Partners's CRMD Position: Q3 2016 in Review

Paloma Partners sold out of CorMedix (CRMD) in Q3 2016, closing a stake of 26,573 shares — an estimated $264K sold.

Paloma Partners first reported a position in CRMD in Q1 2016 and held it in 2 quarters. The position peaked at $264K in Q2 2016. 39 funds tracked by Wall St. Rank hold CRMD as of Q3 2016.

  • Paloma Partners reported no remaining CorMedix position as of Q3 2016 after selling out during the quarter.
  • Paloma Partners sold 26,573 CorMedix shares in Q3 2016, an estimated $264K.
  • Paloma Partners first reported a position in CorMedix in Q1 2016 and held it in 2 quarters.
  • Paloma Partners's CorMedix position peaked at $264K in Q2 2016.
  • 39 funds tracked by Wall St. Rank held CorMedix as of Q3 2016.

Based on Paloma Partners's 13F filing for Q3 2016, filed 14 Nov 2016.